Little Hiccup Costs Affy $10M-$12M in Q3; ParAllele Acquisition Delayed to Q4

While Affy said that the pressure has been let off for the near term and has pledged to invest more in manufacturing, it will be careful about claiming [that] anything is resolved," officials said. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.